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AbstrAct
Objective To describe the changes in prescribing of oral 
anticoagulant (AC) and antiplatelet (AP) agents in patients 
with non-valvular atrial fibrillation (NVAF) in the UK and to 
identify the characteristics associated with deviation from 
guideline-based recommendations.
Design Five cross-sectional analyses in a large 
retrospective population-based cohort study.
setting General practices contributing data to the UK 
Clinical Practice Research Datalink.
Participants The study included patients with a diagnosis 
of NVAF and eligible for anticoagulation (CHA
2DS2-VASc 
score ≥2) on 1 April of 2012, 2013, 2014, 2015 and 1st 
January 2016.
results The proportion of patients being treated with 
AC increased at each index date, showing an absolute 
rise of 16.7% over the study period. At the same time, 
the proportion of patients treated with an AP alone was 
reduced by half, showing an absolute decrease of 16.8%. 
The proportion of patients not receiving any antithrombotic 
(AT) treatment remained the same across the study period. 
A number of predictors were identified for AP alone or no 
treatment compared with AC treatment.
conclusion Major improvements in the AT management 
of patients with NVAF for stroke prevention in the UK were 
observed between April 2012 and January 2016. Despite 
this, nearly 20% of at-risk patients still received AP alone 
and over 15% were on no AT agents in January 2016.
IntrODuctIOn
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia,1 estimated to affect up to 
35 million people worldwide,2 with 1.4 million 
people affected in England alone.3 AF is an 
independent risk factor for stroke, increasing 
the risk five-fold.4
Approximately 20% of stroke cases in the 
UK are thought to have AF as a contributing 
factor, and AF-related strokes are more likely 
to be fatal or cause severe disability than 
non-AF related strokes.5 6 However, AF-re-
lated strokes can be prevented and their 
impact minimised by effective management 
strategies including increased detection of 
AF, adherence to stroke prevention guide-
lines and anticoagulant (AC) use in at-risk 
patients.
Although AC use is effective in preventing 
strokes due to AF, evidence suggests AC 
therapy remains underused.7–13 In 2010, 
Holt et al9 showed that only 50.7% of patients 
with non-valvular AF (NVAF) at high risk of 
stroke in the UK were treated with oral AC. 
Opportunities to impact significantly on an 
important cause of cardiovascular morbidity 
and mortality are thereby frequently missed.
In 2012, a focused update of the 2010 Euro-
pean Society of Cardiology (ESC) guidelines 
for the management of AF was issued.14 This 
update included three major changes based 
on new or strengthened evidence. First, the 
CHA2DS2-VASc score replaced the CHADS2 
score for the assessment of stroke risk. This 
was based on the accumulated evidence that 
the CHA2DS2-VASc score, which is inclusive 
of the most common risk factors for stroke15 
and has been validated in multiple cohorts,16 
is better at identifying patients at ‘truly low 
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Research
strengths and limitations of this study
 ► A large representative population of patients with all 
forms of atrial fibrillation (paroxysmal and chronic) 
studied in the ‘real-world’ using data obtained from 
general practitioner  records in Clinical Research 
Practice Datalink (CPRD).
 ► Real-world data are more likely to reflect wider 
contemporary treatment practices than information 
obtained from registries.
 ► Although CPRD is regularly and extensively audited 
to ensure data quality, the study is limited by the 
accuracy of GP records.
 ► The completeness of the GP record is difficult to 
ascertain, and we may have not detected some 
individuals receiving anticoagulant prescriptions 
in secondary care.
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risk’ of AF-related stroke.17–20 Second, the use of aspirin 
therapy for stroke prevention in AF was restricted to those 
patients who refuse oral AC. Third, the use of non-vi-
tamin K antagonist oral anticoagulants (Novel Oral ACs 
(NOACs) such as dabigatran, apixaban and rivaroxaban) 
was recommended in preference to vitamin K antagonists 
(VKAs such as warfarin) in most patients with a CHA2DS2-
VASc score ≥1.14
Despite these guidelines and the weight of evidence, 
national audit data from the UK showed that among 
patients with known AF admitted to hospital for stroke 
between January and March 2013, 38% were taking anti-
platelet (AP) drugs alone.21
In 2014, when the National Institute for Health and 
Care Excellence (NICE) updated its AF clinical guide-
lines (CG180),22 it recommended that NOACs should be 
considered as equal first-line options alongside warfarin 
for NVAF; furthermore, in a significant change to estab-
lished practice stated that aspirin should not be used as 
monotherapy to prevent AF-related stroke. The Royal 
Colleges published a consensus statement reiterating 
this advice and emphasising the importance of ensuring 
patients are supported to make an informed choice of 
AC.23
It is not yet known whether the update of the ESC and 
NICE guidelines effectively impacted treatment practices 
in the UK. Therefore, this study aims to describe the 
changes in primary care prescribing of oral AC and AP 
agents in patients with NVAF eligible for anticoagulation 
during the years 2012–2016 and to identify clinical char-
acteristics associated with deviation from guideline-based 
recommendations.
MethODs
Data source
Data were obtained from the UK Clinical Practice 
Research Datalink (CPRD).24 The CPRD is an anony-
mised primary care database established in 1987 to 
collect longitudinal medical records data from general 
practitioner (GP) practices. As of April 2013, the CPRD 
covered 674 GP practices with 4.4 million active patients 
(ie, patients that are alive and registered), reflecting 
approximately 6.8% of the UK population. This active 
sample is representative of the UK population in terms 
of age, sex and ethnicity. The CPRD contains patient 
registration information as well as events that the GP 
records during routine clinical practice, including 
medical diagnoses, prescriptions issued, anthropometric 
measurements, diagnostic tests, lifestyle information 
(eg, smoking status and alcohol intake) and referrals to 
secondary care.
The CPRD has broad National Research Ethics Service 
Committee (NRES) ethics approval for purely obser-
vational research. This study protocol was approved 
by the Medicines and Healthcare products Regulatory 
Angency (MHRA) Independent Scientific Advisory 
Committee (protocol 14_245R).
study population
All patients with a diagnosis of NVAF and eligible for 
anticoagulation according to ESC 201214 and NICE23 
guidance at index date (CHA2DS2-VASc score ≥2) were 
included in five cross-sectional analyses: on 1 April of 
2012, 2013, 2014 and 2015 and 1 January of 2016 (index 
date for each year). Patients were further required to be 
at least 18 years old at the index date, have had at least 
one consultation with their GP in the last 12 months, 
have ongoing CPRD registration and have at least 12 
months of computerised medical data prior to the index 
date. Patients were excluded from the study if they had 
a valvular condition (eg, rheumatic mitral or aortic 
valve disease, or prosthetic valve; codes used to identify 
patients are in the data supplement) or if their gender 
was unknown. Figure 1 summarises the patient selection 
process.
study variables
Exposure to AC was defined by the last anticoagulation 
prescription identified in the 90-day period preceding 
the index date. Three type of regimens were defined: 
AC, AP alone or no antithrombotic (AT) treatment. AC 
included VKAs, apixaban, rivaroxaban, dabigatran and 
parenteral AC. International normalised ratio (INR) 
measurements were treated as an indicator of VKA expo-
sure and used to extend VKA exposure time. Exposure 
to AP alone was defined by an absence of AC prescrip-
tion and the presence of at least one AP prescription in 
the 90-day period preceding the index date. No AT was 
defined by the absence of AC or AP prescription in the 
90-day period preceding the index data. A 90-day period 
has been used in previous studies to identify recent treat-
ment exposure.25
Demographic characteristics included age, gender and 
country of residence. Clinical characteristics were body 
mass index, smoking status, time since NVAF diagnosis, 
stroke risk factors (previous stroke, transient ischaemic 
attack (TIA) or other arterial thromboembolism, conges-
tive heart failure (CHF), coronary artery disease, periph-
eral artery disease, hypertension or diabetes mellitus), 
other bleeding risk factors (previous bleeds, peptic ulcer, 
renal disease, liver disease, concomitant treatment with 
AP or non-steroidal anti-inflammatory drugs or high 
alcohol intake), falls, active cancer (at least one diagnosis 
related to cancer in the last 12 months) and number of 
concomitant treatments (prescribed in the last 90 days). 
The CHA2DS2-VASc score and a modified HAS-BLED 
score (excluding INR component as not consistently 
reported in CPRD, score range: 0–8) were calculated for 
all patients. All clinical diagnoses were identified using 
Readead codes (codes lists provided in the data supple-
ment). Diabetes and hypertension were also identified 
using the prescription of antidiabetic or antihypertensive 
treatments.
statistical analyses
The proportion of patients treated with each regimen 
(AC, AP alone or no AT) and their 95% CI were calculated 
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Figure 1 Flow chart describing the sample used in each year. AF, atrial fibrillation; GP, general practitioner; NVAF, non-valvular 
atrial fibrillation.
at each index date. As the CPRD does not provide sample 
survey weights, it is only possible to estimate proportions 
as if the CPRD data is a simple random sample of approx-
imately 8% of UK GPs/patients, so a finite population 
correction factor of 0.96 was applied to the standard 
errors of proportion estimates (FPCF=√(1–0.08)~0.96).
An interrupted time series analysis26 was conducted 
to estimate the impact of the updated ESC guidance 
(published in August 2012) and NICE 201423 guidance 
(published in June 2014) on the evolution of the propor-
tion of patients treated with each regimen, controlling for 
baseline level and trend. For this analysis, data from April 
2011 to April 2015 were used, and month-by-month esti-
mates were extracted to obtain 50 time-points (using the 
same inclusion criteria than for the five main cross-sec-
tional analyses). The time series model was divided into 
three time periods: (1) pre-ESC guidelines, (2) post-ESC 
guidelines and (3) post-NICE guidelines. The statistical 
significance of the change in level (ie, the rapid drop in 
rates immediately after the intervention) and trend (ie, 
the gradual decline in rates over the remainder of the 
follow-up period) were tested for each time period. The 
slope in each time period was calculated by summing 
the change in trend observed in the time period and the 
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previous slope (in first period (pre-ESC), the baseline 
trend was equal to the slope).
These analyses of the evolution of the AT manage-
ment over time were also run separately in newly diag-
nosed patients with NVAF (<12 months) and in patients 
with NVAF with a diagnosis for ≥12 months, as well as in 
each country of residence separately (England, Scotland, 
Wales and Northern Ireland; results by country provided 
in the data supplement).
Generalised estimating equations (GEEs) were used to 
identify demographic and clinical characteristics associ-
ated with AP treatment and with the absence of AT treat-
ment (vs receiving AC) in April 2015 (date of the last 
planned cross-sectional analysis). The final models were 
obtained using a backward elimination until all variables 
were significantly associated with the outcome (p<0.05). 
Models were adjusted for clustering within individuals 
and within GP practices, and results are given as ORs and 
95% CIs.
sensitivity analyses
To evaluate the proportion of patients that could have 
been misclassified as untreated, a sensitivity analysis was 
conducted, extending the exposure window used to clas-
sify patients to 180 days prior to index date. To assess the 
possible impact of GP sample modification, a second 
sensitivity analysis limiting the study sample to only those 
patients who were registered to a GP practice included in 
the CPRD throughout the study period.
All analyses were conducted using SAS software V.9.4.
results
Patient characteristics
The demographic and clinical characteristics of patients 
with NVAF eligible for anticoagulation according to ESC 
and NICE guidance (CHA2DS2-VASc ≥2) from April 2012 
to January 2016 are provided in table 1. The character-
istics of the population were consistent across the study 
period: patients’ mean age was 78 years, 52.4%–54.3% 
were male and more than 50% were either overweight or 
obese. Almost 20% had a history of stroke or TIA, around 
30% had a history of coronary artery disease and most 
had hypertension (>97%). Approximately 12% had been 
diagnosed with NVAF within the preceding 12 months 
(newly diagnosed).
treatment patterns over time
The proportion of patients being treated with AC 
increased each year, showing an absolute rise of 16.7% 
over the study period (from 50.2% in April 2012 to 66.9% 
in January 2016) (table 2). At the same time, the propor-
tion of patients treated with an AP alone was reduced by 
half, showing an absolute decrease of 16.8% (from 34.2% 
in April 2012 to 17.4% January 2016). The proportion 
of patients not receiving any AT treatment remained 
the same across the study period, at around 15% of all 
patients with NVAF.
Stratifying the population by time since diagnosis iden-
tified the reduction in the proportion of patients treated 
with AP alone was greater in newly diagnosed patients, 
relative to those who had been diagnosed for ≥12 months 
(26.8% vs 15.4%). In January 2016, only 11.3% of the 
newly diagnosed patients were treated with AP alone (vs 
18.3% of those diagnosed ≥12 months). Similarly, the 
increase in the proportion of patients being prescribed 
AC was greater in those patients who were newly diag-
nosed compared with those diagnosed with NVAF for ≥12 
months (25.3% vs 15.5%). In January 2016, 72.5% of the 
newly diagnosed patients were treated with AC (vs 66.1% 
of those diagnosed for ≥12 months).
In newly diagnosed patients, major changes in the type 
of oral AC prescribed were observed between April 2014 
and January 2016. The proportion of patients initiated 
with VKA fell from 50.8% to 31.8% of all patients with 
NVAF, while the NOAC prescriptions rose from 9.8% to 
40.6% (including 16.6% apixaban, 2.4% dabigatran and 
21.5% rivaroxaban). No major change was observed in 
the NVAF population with a diagnosis for ≥12 months; 
VKA was prescribed in 50.9% of the population in January 
2016 and NOACs in 15% (including 4.5% apixaban, 2.2% 
dabigatran and 8.3% rivaroxaban).
A sensitivity analysis using a time period of 180 days 
prior to index date was used to evaluate the propor-
tion of patients that could have been misclassified as 
untreated. This analysis provided the same results, with 
only 2% difference in the proportion of untreated 
patients observed. Results were also unchanged when 
restricting only to those patients who were registered to 
a GP included in the CPRD throughout the study period.
Impact of esc and nIce guidelines publications on uK practice
The time series analysis stratified by time since NVAF 
diagnosis (<12 months or ≥12 months) showed that there 
was a significant trend for increasing AC treatment in 
both patient groups since April 2011 (table 3). However, 
a significant acceleration of this trend (increase of the 
slope) was observed after the updated ESC guidance 
publication (change in trend: β=+0.26 in newly diag-
nosed, β=+0.18 in patients diagnosed ≥12 months) and 
also after NICE guidance publication (change in trend: 
β=+0.12 in newly diagnosed, β=+0.15 in patients diag-
nosed ≥12 months).
Equally, a significant trend for decreasing AP use was 
observed since April 2011. A significant acceleration of 
this trend was observed after both ESC and NICE guid-
ance publications. This change in trend was more marked 
after ESC for the newly diagnosed patients (post-ESC: 
β=−0.26, post-NICE: β=−0.10) and after NICE for patients 
diagnosed ≥12 months (post-ESC: β=−0.15, post-NICE: 
β=−0.21).
characteristics associated with the absence of Ac therapy in 
April 2015
Tables 4 and 5 present the results of the GEE models 
comparing demographic and clinical characteristics in 
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patients receiving either an AP alone or no AT, versus 
those receiving AC treatment in April 2015. Even after 
adjusting on CHA2DS2-VASc score, females and patients 
aged <65 or ≥85 (vs patients 65–74 years) were more likely 
to be prescribed an AP alone or no AT treatment, whereas 
patients with a history of stroke/TIA, CHF or hyperten-
sion were less likely to remain untreated. The likelihood 
of being treated with AP alone increased with time since 
diagnosis. Patients with coronary and peripheral artery 
disease were also more likely to be treated with an AP 
alone than AC. Importantly, CHA2DS2-VASc was associ-
ated with the absence of AT treatment, and patients with a 
score ≥3 were less likely to remain untreated than patients 
with a CHA2DS2-VASc score=2. To less extent, the same 
association was observed in patients treated with AP alone 
(vs AC). Patients who had a previous intracranial bleed 
were more likely to be treated with AP and even more 
likely to remain untreated. The absence of any AT was 
more frequent in patients with less than five comedica-
tions. Geographic variations were observed, with a higher 
proportion receiving AP alone or no AT in England and 
Scotland compared with Wales and Northern Ireland.
DIscussIOn
A pronounced shift in AC management of patients with 
NVAF was observed in the UK between April 2012 and 
January 2016, coinciding with the update of ESC14 and 
NICE22 guidelines and with the availability of the NOACs 
as an alternative to VKAs. A substantial increase in the 
proportion of patients with NVAF at risk of stroke treated 
with AC was observed during this time (from 50.2% to 
66.9%), as well as an important decrease of AP use (34.2% 
to 17.4%).
Whereas important increases in the proportion of 
patients with NVAF treated with AC were previously 
described in the UK between 1994 and 2003,7 8 no signif-
icant changes were observed in the years 2007–2010 in 
patients with CHA2DS2-VASc ≥2, with AC use remaining low 
(around 50%) and AP alone widely used (36%). The high 
use of AP until March 2012 may have also partly reflected 
the recommendations of the Quality and Outcomes 
Framework of the National Health Service (NHS), which 
provided equal emphasis on AC and AP in stroke preven-
tion in primary care at that time.13
The observed shift in treatment patterns in this study 
suggests a positive impact of both the ESC14 and NICE22 
guidelines in driving changes in thrombopropylaxis 
strategy for patients with NVAF in the UK, most notably 
the move away from AP use. The release of the ESC guid-
ance appeared to impact more significantly the manage-
ment of recently diagnosed patients. This may reflect an 
earlier change in the practice of cardiologists who, in 
the UK, are typically more involved in the diagnosis and 
initial management of NVAF. Indeed, the publication of 
the NICE guidance had a greater impact on the decline 
in AP use among patients with a pre-existing diagnosis, 
which might reflect the higher impact of local guidance 
group.bmj.com on September 28, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
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Table 2 Evolution of the proportion of patients treated with anticoagulants, with antiplatelet therapy alone or no 
antithrombotic therapy among patients with NVAF with CHA2DS2-VASc ≥2
April 2012
% (95% CI)
April 2013
% (95% CI)
April 2014
% (95% CI)
April 2015
% (95% CI)
January 2016
% (95% CI)
Anticoagulation 50.2 (49.8 to 50.5) 53.2 (52.8 to 53.5) 57.5 (57.1 to 57.9) 62.9 (62.5 to 63.3) 66.9 (66.5 to 67.3)
Antiplatelet therapy 
alone
34.2 (33.9 to 34.5) 31.2 (30.8 to 31.5) 27.7 (27.3 to 28.0) 21.8 (21.5 to 22.2) 17.4 (17.1 to 17.8)
No antithrombotic 
therapy
15.6 (15.4 to 15.9) 15.7 (15.4 to 15.9) 14.8 (14.6 to 15.1) 15.3 (15.0 to 15.6) 15.7 (15.4 to 16.0)
Table 3 Time series analysis describing the trends in the evolution of the proportion of patients with NVAF treated with 
anticoagulants, aspirin or other AP therapy alone or without any antithrombotic treatment from April 2012 to April 2015 in the 
UK by time since NVAF diagnosis
Pre-ESC* Post-ESC† Post-NICE†
β SE p Value β SE p Value β SE p Value
A. Anticoagulation treatment
Diagnosed <12 months
  Level 43.09 0.26 <0.0001 0.28 0.35 0.418 0.10 0.49 0.846
  Trend 0.34 0.02 <0.0001 0.26 0.03 <0.0001 0.12 0.09 0.171
Diagnosed ≥12 months
  Level 49.01 0.07 <0.0001 0.00 0.10 0.981 −0.16 0.14 0.251
  Trend 0.13 0.01 <0.0001 0.18 0.01 <0.0001 0.15 0.02 <0.0001
B. Aspirin (ASA) or other AP only
Diagnosed <12 months
  Level 41.94 0.24 <0.0001 −0.20 0.31 0.518 −0.63 0.44 0.159
  Trend −0.36 0.02 <0.0001 −0.26 0.03 <0.0001 −0.10 0.08 0.226
Diagnosed ≥12 months
  Level 35.05 0.06 <0.0001 0.03 0.08 0.737 −0.33 0.12 0.008
  Trend −0.12 0.01 <0.0001 −0.15 0.01 <0.0001 −0.21 0.02 <0.0001
C. Without any antithrombotic treatment
Diagnosed <12 months
  Level 14.97 0.15 <0.0001 −0.08 0.19 0.6835 0.54 0.27 0.057
  Trend 0.02 0.01 0.211 0.00 0.02 0.9262 −0.03 0.05 0.612
Diagnosed ≥12 months
  Level 15.94 0.07 <0.0001 −0.03 0.10 0.789 0.49 0.14 0.001
  Trend −0.01 0.01 0.174 −0.03 0.01 0.000 0.06 0.02 0.015
*Pre-ESC data are base level, base trend.
†Post-ESC and post-NICE data are change in level, change in trend.
AP, antiplatelet; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence; NVAF, non-valvular atrial 
fibrillation.
on GPs who are more involved in the long-term manage-
ment of patients.
Overall, the most marked improvement in stroke 
prevention in AF occurred in newly diagnosed patients, 
in whom AC prescriptions rose from 47.2% to 72.5% and 
the use of AP alone dropped to 11.3% in January 2016. 
At the time of diagnosis, patients are likely to be partic-
ularly engaged with their condition, more likely to be 
booked for further clinical assessment and physicians are 
obligated to make a decision regarding AC. Conversely, 
patients with a long-standing diagnosis may be more resis-
tant to changes in their treatment regimen, and throm-
boembolism prophylaxis may not be the focus of clinical 
appointments. As newly diagnosed patients represent 
only 20% of the NVAF population, this emphasises the 
potential impact on stroke prevention in the UK that 
could be achieved by effectively addressing thromboem-
bolism prophylaxis strategy in patients with an established 
NVAF diagnosis. Ongoing educational activity and the use 
of specialist nurses and pharmacist-led anticoagulation 
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clinics will play an important role in reaching this group 
of patients.
Importantly, the trend for increasing use of AC between 
2012 and 2016 was associated with the growing use of 
NOACs (apixaban, rivaroxaban and dabigatran). This 
growth of NOAC use was mainly observed in newly diag-
nosed patients between 2014 and 2016, associated with a 
decrease of VKA initiation and coincided with the release 
of NICE guidance22 and the Consensus Statement reit-
erating that NICE-approved treatments have to be made 
available for prescribing. This highlights the vital role of 
the NOACs as alternatives to VKA through addressing 
some of the limitations of VKA therapy and responding 
to individual patient needs. However, in patients who had 
been diagnosed for ≥12 months, no major changes in the 
proportion treated with VKA were observed, indicating 
significant VKA inertia in this group.
This growing trend in the use of NOACs in newly diag-
nosed patients with AF can be linked to a growing aware-
ness raised through NICE guidance about the benefits 
of NOAC treatment and to an increased attentiveness to 
AF detection. Currently, only opportunistic screening for 
AF is implemented: NICE recommends an ECG to diag-
nose AF in patients who present with irregular pulse.22 An 
expansion in AF screening would potentially result in the 
earlier detection of AF in asymptomatic patients and thus 
the early provision of prophylactic OAC treatment.
Although these data show that AC treatment patterns in 
NVAF have improved substantially over the last 5 years, rates 
of anticoagulation appear to lag behind those observed in 
contemporary European cohorts. For example, at the 2-year 
follow-up of the EurObservational Research Programme 
- Atrial Fibrillation (EORP-AF) registry in 2015, 79.2% of 
patients with AF were identified as receiving at least one oral 
AC (compared with 62.9% in 2015 in this study, table 2).27 
Rates of NOAC use however appear more comparable, with 
13.7% of patients in EORP-AF receiving at least one NOAC 
(compared with 10.9% in this study in 2015). Baseline data 
from the European population of the Global Registry on 
Long-Term Oral Antithrombotic Treatment in Patients with 
Atrial Fibrillation (GLORIA-AF) registry, which includes 
only newly diagnosed AF patients, showed the majority 
(52.4%) were treated with NOACs, while 5.7% received AP 
therapy and only 4.1% remained untreated.28 These data 
are comparable with the 9.8% receiving NOACs, 23.8% AP 
therapy and 15.2% untreated among patients diagnosed 
between 2013 and 2014 in our study (figure 2). Similarly, 
in the global Global Anticoagulant Registry in the Field - 
Atrial Fibrillation (GARFIELD-AF) registry of patients with 
very recently diagnosed NVAF (<6 weeks), over the period 
from 2010/2011 to 2014/2015, the proportion of patients 
treated with AC increased from 57.4% to 71.1% including 
a significant increase in the proportion receiving NOACs 
(4.2%–37.0%), while AP monotherapy declined from 
30.2% to 16.6%.29 It is encouraging that our data up to 
January 2016 continue to show AC use is increasing in the 
UK. Differences with European-based cohorts may, there-
fore, reflect a time lag associated with the later release of 
NICE guidance in 201422 relative to the ESC guidance in 
2012.14 Other factors may also be involved. The time lag 
between guideline recommendation and routine clinical 
practice should be considered with the release of newer 
ESC guidance in 2016.30
Whereas the striking decrease of AP use observed in 
this study is encouraging, the absence of any changes in 
the proportion of patients remaining untreated raises 
some concerns. These current data identify patient char-
acteristics associated with remaining untreated. Younger 
patients (<65 years), patients taking fewer prescription 
medications (<5) and those with a CHA2DS2-VASc score 
of 2 were all more likely to remain untreated. We hypoth-
esise that this could be secondary to a misperception of 
stroke risk by clinicians, but it may also be secondary to 
patient attitude. Furthermore for those patients <65 years 
of age, the monitoring requirements of VKAs may be 
regarded as incompatible with a working life, a barrier 
that could be overcome with the use of NOACs.
At the other end of the spectrum, elderly patients (>85 
years) were found to be less likely to be prescribed AC 
therapy and more likely to be treated with AP alone. 
This observation is well documented8 12 13 31–35 and may 
be secondary to an overestimation of bleeding risk 
despite unequivocal evidence of the benefits of AC in the 
elderly.36–39
Our findings clearly illustrate the risk–treatment 
paradox previously reported in AF management12 that 
patients at higher risk of stroke who are more likely to 
benefit from AC therapy38 are not receiving appropriate 
treatment, perhaps because of a perceived increased risk 
of bleeding. In fact, several bleeding risk factors such as 
falls, peptic ulcer disease, anaemia and previous risk of 
intracranial or gastrointestinal bleeds were found to also 
be associated with an increasing likelihood of remaining 
untreated. A survey of UK general practices from 2000 
to 2009 showed that this underuse of AC therapy in the 
elderly is not adequately explained by either an increase 
in comorbidities or bleeding risk.40
In addition to age, female patients were found less 
likely to be treated with AC. This sex difference in 
prescribing has been previously observed in a UK study 
in AF.8 Given that women with AF appear to lose their 
protection against sudden death including stroke41 and 
may even have a higher mortality than men,42 these lower 
AC rates are a cause for concern. AP alone was found to 
be prescribed more frequently in patients with coronary 
artery disease. This may highlight the lack of a definitive 
evidence base and clear guidance on the AT manage-
ment of these patients, particularly in the initial period 
following an acute coronary syndrome.
Collectively, the results indicate a strong mandate to 
change current clinical practice to improve prescribing 
patterns among treating clinicians. This is further empha-
sised by the 2016 ESC guidelines, which state that aspirin 
monotherapy should not be used for stroke prevention in 
patients with AF regardless of stroke risk and may in fact 
cause harm.30 Although the present study was conducted 
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Figure 2 Evolution of the proportion of patients treated with each anticoagulant, with antiplatelet therapy alone or no 
antithrombotic therapy among patients with NVAF with CHA2DS2-VASc ≥2 separately in newly diagnosed patients (A) and 
patients diagnosed since 12 months or more (B). NOACs, novel oral anticoagulants; VKAs, vitamin K antagonists.
in the UK, the finding that a considerable number of 
patients with AF continue to be undertreated has wider 
implications for stroke prevention in AF, which remains 
a global issue.
strengths and limitations
This is a large study of a representative population of 
patients with NVAF managed in the UK. It includes 
patients with all forms of AF, including paroxysmal and 
chronic. The study may have not detected some indi-
viduals receiving AC prescriptions in secondary care. 
The National Patient Safety Agency has emphasised the 
importance of good communication between different 
bodies sharing responsibility for prescribing potentially 
interacting medication, and this has increased the use 
of codes in primary care to maintain awareness of AC 
therapy prescribed elsewhere.9 43
This study is based on a general practice database and 
is limited by the accuracy of GP records. Validation of the 
CPRD has shown high positive predictive value of some 
diagnoses and, where evaluated, comparisons of incidence 
with other UK data sources are also broadly similar.44 
However, the completeness of the record is more difficult 
to ascertain. We acknowledge that the results reported in 
this study may under-represent comorbidities and, hence, 
overall stroke risk.
It is important to note that due to the falling number 
of GP practices involved in the CRPD, the number of 
eligible patients with NVAF also fell during the study 
period. However, a sensitivity analysis was conducted on 
the NVAF population who were registered to a GP prac-
tice included in the CPRD throughout the study period, 
and the results were unchanged. Therefore, the observed 
change in AT management cannot be attributed to the 
reduction in available GP data.
It is important to reflect on the differences in the nature 
of data collection and analysis between registry and real 
world healthcare records, whereby participation in a 
registry may influence treatment selection but allow more 
complete and accurate data collection, whereas real world 
datasets allow analysis of much larger cohorts that are more 
likely to reflect wider contemporary practice, although with 
less complete and well-validated data.
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cOnclusIOn
Major improvements in the AC management of patients 
with NVAF for stroke prevention in the UK were observed 
between April 2012 and January 2016. Despite this, 20% of 
the at-risk population were still treated with AP alone and 
more than 15% of patients were on no AT agents in January 
2016. However, if the trend of rapid reduction of AP use 
observed during the study period continues, then the use of 
AP alone for stroke prevention could essentially disappear 
in the next few years in the UK. The consistency observed 
over time in the proportion of patients not treated with 
any AT therapy represents the area of greatest concern. 
The clinical inertia seen in this group may be due to an 
underestimate of the risk of stroke in these patients who 
were found to be younger with less comorbidities, and the 
overestimation of bleeding risk in the elderly (>85 years). 
There remains a huge potential for reducing the stroke risk 
of the AF population by improving the thromboembolic 
risk assessment in NVAF in primary care and the identifica-
tion of patients requiring AC.
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